Poster 1002: Galectin-3 as predictive biomarker of airways remodeling modulation in omalizumab treated severe asthma patients

Pierluigi Mauri(Institute of Biomedical Technologies), Giorgio Walter Canonica(Humanitas University), A Riccio(University of Palermo), Rossana Rossi(University of Parma), Louise Benazzi(Institute of Genetic and Biomedical Research), Roberto W. Dal Negro, Laura De Ferrari(Istituti di Ricovero e Cura a Carattere Scientifico), Dario Di Silvestri
World Allergy Organization Journal
January 1, 2014
10.1186/1939-4551-7-s1-p3
Cited by 4

Related Papers

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k